Management Team

Deborah Ramsdell

Chief Executive Officer

  • 25+ years as a drug development executive
  • Founded and managed own consulting firm for 18 years
  • Most recently VP Regulatory Affairs and Clinical Operations at Enobia Pharma prior to acquisition by Alexion Pharma

Dustin Armstrong, Ph.D.

Chief Scientific Officer

  • Founded Valerion (formerly 4s3 Bioscience)
  • Leads the scientific research effort for preclinical pipeline candidates and platform
  • Prior to founding Valerion worked at Novartis’  Global Research & Development Center, Cambridge, MA

Hal Landy, MD

Chief Medical Officer

  • Board certified Pediatric Endocrinologist with 25+ years of clinical research experience in academics and industry and over 20 publications, primarily in rare orphan diseases
  • VP positions at Serono, Genzyme & Repligen with numerous successful drug approvals in growth, wasting and lysosomal disorders in the US, EU, Canada and Japan
  • Most recently CMO and VP, Medical Affairs Enobia Pharma prior to acquisition by Alexion Pharma and Medical Consultant to Lotus Tissue Repair

David Ramsdell

Chief Financial Officer

  • 25+ years as CFO in multiple industries including life science, computer software, technology market research, product distribution
  • Most recently CFO for Alopexx companies, partner at Tatum LLC, consultant to multiple technology companies
  • MBA, Amos Tuck School, Dartmouth College. AB Economics, Colorado College

Board of Directors

Deborah Ramsdell

President, CEO

Dustin Armstrong, Ph.D.

Secretary, Treasurer, Chief Scientific Officer

Randy Wingate

Board Member

Christine del los Reyes

Board Member, Business Development Consultant

Daniel Vlock

Chairman of the Board of Directors